In situ vaccination (ISV) combining Flt3L, local radiotherapy, and a TLR3 agonist, led to systemic clinical cancer remission and potentiation of PD-1 blockade in patients with advanced stage indolent non-Hodgkin’s lymphomas (iNHLs) [42]. Here, FLT3LG is linked to cancer.